Tag Archives: Lemtrada

Is Sanofi Right to Bank on MS Drug?

Newswires have long been waiting for Sanofi-Aventis to officially announce its acquisition of US biotech company Genzyme, but what few analysts were expecting is just how much the transaction would hedge on one potentially controversial product. As the focus of Sanofi’s contingent value rights (CVR) approach, Genzyme’s multiple sclerosis treatment Lemtrada (also sold as Campath […]
Posted in pricing, Safety, Strategy | Also tagged , , , , | 1 Comment
  • Categories

  • Meta